IL HB0004: MEDICAID-PHARMACY SERVICES
Illinois HB0004 proposes changes to Medicaid pharmacy services, potentially affecting reimbursement and coverage for pharmaceutical manufacturers. The bill may alter how drugs are dispensed under Medicaid, impacting branded, generic, API, and compounding manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers operating in Illinois, including branded, generic/ANDA, API & contract, and compounding outsourcing (503B) facilities. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Monitor legislative progress; bill may be enacted in current session. No immediate deadline, but early engagement recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill modifies Medicaid pharmacy services, possibly affecting drug reimbursement rates, coverage criteria, or dispensing requirements.
Who it affects
Pharmaceutical manufacturers operating in Illinois, including branded, generic/ANDA, API & contract, and compounding outsourcing (503B) facilities.
What you must do
Review the full bill text to understand specific changes to Medicaid pharmacy services and assess impact on product reimbursement and market access.
Deadline
Monitor legislative progress; bill may be enacted in current session. No immediate deadline, but early engagement recommended.
Source: https://ilga.gov/Legislation/RegularSession/HB?SessionId=114
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications